Temple Acquires London Longevity Practice Longevous

Overview

• The acquisition, announced Thursday, August 27, 2026, brings Longevous founders Dr Robert Mohr and Dr Avi Roy and their team into Temple full time with Mohr named chief medical officer and Roy named head of science.
• Mohr, a board-certified physician with nearly two decades of clinical experience, will oversee clinical rigour for Temple’s experiments and health claims while Roy, an Oxford-trained biomedical scientist, will lead Temple’s research efforts.
• Mohr and Roy had already worked with Temple’s science team for months to pressure-test the company’s proprietary Entropy metric, review wearable data and vet the startup’s first scientific manuscripts prior to submission.
• Longevous will continue operating under Temple and its existing clients will be served by Mohr and Roy, while Temple did not disclose financial terms of the acquisition.
• The move strengthens Temple’s ability to produce validated science and manuscripts needed for credibility and commercialization, reflecting a wider pattern of consumer health device companies buying clinical teams to support product launches.